Physician profile
Case Tedder
NPI 1194111732
$613.22
in general payments reported to CMS, 2019-2025
13 companies · $103 in 2025
The $103 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $156 · 2020: $79.75 · 2021: $92.73 · 2023: $107 · 2024: $74.45 · 2025: $103.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $284.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $284.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $153.36 | 2019-2023 | Farxiga |
| Novo Nordisk INC | $105.78 | 2019-2025 | Ozempic |
| Abbvie INC. | $83.26 | 2021-2025 | Ubrelvy |
| Pfizer INC. | $66.80 | 2019-2025 | |
| Lilly USA, LLC | $42.41 | 2019-2023 | Mounjaro |
| Amgen INC. | $35.24 | 2025 | Repatha, Otezla |
| Dexcom, INC. | $27.76 | 2024 | Dexcom G6 Transmitter |
| Takeda Pharmaceuticals U.S.A., INC. | $21.62 | 2020 | |
| Glaxosmithkline, LLC. | $21.11 | 2023 | Shingrix |
| Exact Sciences Corporation | $16.74 | 2023 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.02 | 2021 | |
| Janssen Pharmaceuticals, INC | $11.85 | 2019 | |
| Sanofi-Aventis U.S. LLC | $11.27 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Case Tedder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.